Table 4. Alternative Anticoagulants for Treatment of HIT.
Argatroban | Bivalirudin | Fondaparinux | |
---|---|---|---|
Approval | HIT or HIT patients undergoing PCI with or at risk for HIT |
Patients with or at risk of developing HIT during PCI |
Has not received FDA approval for use in HIT |
| |||
Bolus | None | None | N/A |
| |||
Initial dose for isolated HIT or HIT with thrombosis |
1.5-2 mcg/kg/min100 | 0.15-0.2 mg/kg/h59 | < 50 kg: 5 mg SC daily |
50-100 kg: 7.5 mg SC daily | |||
> 100 kg: 10 mg SC daily59 | |||
| |||
Initial dose for renal impairment |
No adjustment necessary126 | 0.08-0.1 mg/kg/h (CrCl 30-60 mL/min) |
Use with caution if CrCl 30-50 mL/min |
0.03-0.05 mg/kg/h (CrCl < 30 mL/min or for patients receiving renal replacement therapy)109 |
Contraindicated if CrCl < 30 mL/min116 | ||
| |||
Initial dose for hepatic impairment |
0.5-1.2 mcg/kg/min100 | No adjustment necessary127 | No adjustment necessary116 |
| |||
Monitoring | Obtain baseline aPTT and 2 hours after starting infusion126 |
Obtain baseline aPTT and 2-3 hours after starting infusion |
Anti-FXa activity can be monitored in renal insufficiency115 |
| |||
Target | aPTT 1.5-3 times the baseline aPTT. Max goal aPTT=100 sec100 |
aPTT 1.5-2.5 times the baseline aPTT59 |
N/A |
| |||
Dosage Adjustment (HIT/HITTS only) |
Adjust infusion by 0.25-0.5 mg/kg/min to achieve goal aPTT. Recheck aPTT 2-4 hours after each dosage change.126 |
Adjust infusion by 20-25% to achieve goal aPTT. Recheck aPTT 2 hours after each dosage change. |
N/A |
| |||
Maximum dose | 10 mcg/kg/min | 0.25 mg/kg/h127 | 10 mg daily116 |
| |||
Transition to warfarin |
Monitor chromogenic FXa level while on combined therapy.101 |
Monitor INR and/or chromogenic FXa while on combined therapy. |
Monitor INR while on combined therapy. Discontinue therapy when INR ≥ 2 for 2 consecutive days116 |
Chromogenic FXa:102 24-45% (INR 2-3) 15-35% (INR 2.5-3.5) |
Chromogenic FXa: 24-45% (INR 2-3) 15-35% (INR 2.5-3.5) |
||
Confirm INR 4-6 hours after infusion is stopped |
|||
| |||
Cost of daily
therapy 107 |
$1313 | $742 | $103 |
| |||
Special considerations |
No antidote is available126 | No antidote is available127 | No antidote is available116 |
HIT in PCI: 0.75 mg/kg bolus followed by a 1.75 mg/kg/h infusion for the duration of the procedure (all subgroups) |
|||
After PCI: 1.75 mg/kg/h (CrCl ≥ 30 mL/min) 1 mg/kg/h (CrCl < 30 mL/min) 0.25 mg/kg/h (hemodialysis) Optional infusion after PCI 0.2 mg/kg/h for 20 hours127 |
Not applicable, N/A; creatinine clearance, CrCl; factor Xa, FX